Recovery Or Purification Patents (Class 435/239)
-
Patent number: 7393527Abstract: A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 1012 pfus and is delivered by direct injection into a group of cancer cells or via intravenous injection.Type: GrantFiled: September 18, 2006Date of Patent: July 1, 2008Assignee: Mayo Foundation for Medical Education and ResearchInventors: Stephen James Russell, Adele Fielding, Kah-Whye Peng, Deanna Grote
-
Publication number: 20080153770Abstract: The present invention relates to the use of internal promoters in mammalian expression vectors including plasmid vectors and enhancer-deleted retroviral vectors. The retroviral vectors have improved safety and optimal levels of transgene expression and vector titers.Type: ApplicationFiled: October 10, 2007Publication date: June 26, 2008Applicant: ViroMed Co., Ltd.Inventors: Sunyoung KIM, Sujeong KIM, Jun-Tae LEE
-
Publication number: 20080124304Abstract: The present invention relates to a method for generating virus producing cell lines and master producer cell lines. In particular, the present invention relates to methods allowing the production of virus producing cell lines without conducting laborious selection work. Moreover, the present invention pertains to virus producing cell lines obtained with the methods according to the present invention as well as to virus obtained using said cell lines.Type: ApplicationFiled: November 1, 2005Publication date: May 29, 2008Inventors: Dagmar Wirth, Hansjoerg Hauser, Roland Schucht
-
Publication number: 20080124356Abstract: The invention relates to keratinocyte culture, a keratinocyte culturing method and the use thereof for spreading living attenuated viruses. The inventive method makes it possible to obtain living attenuated viruses and vaccines containing said viruses.Type: ApplicationFiled: July 15, 2004Publication date: May 29, 2008Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe Djian, Amandine Laetitia Vanessa Vanhoutteghem
-
Publication number: 20080118468Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.Type: ApplicationFiled: September 3, 2004Publication date: May 22, 2008Applicant: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Shanmuga Sozhamamnnan, Gary R. Pasternack
-
Publication number: 20080112973Abstract: The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.Type: ApplicationFiled: May 25, 2007Publication date: May 15, 2008Inventors: Douglas R. Lowy, John T. Schiller, Heather Greenstone
-
Patent number: 7364893Abstract: The present invention provides recombinant and/or isolated infectious laryngotracheitis virus glycoproteins, including gD, gI, gG and gE.Type: GrantFiled: January 27, 2006Date of Patent: April 29, 2008Assignee: Schering-Plough Animal Health Corp.Inventors: Martha A. Wild, Mark D. Cochran
-
Patent number: 7361496Abstract: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.Type: GrantFiled: August 2, 2000Date of Patent: April 22, 2008Assignee: WyethInventors: David K. Clarke, J. Erik Johnson, Mohinderjit S. Sidhu, Stephen A. Udem
-
Patent number: 7344723Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5?-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G-->A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.Type: GrantFiled: February 27, 2004Date of Patent: March 18, 2008Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: George Kukolj, Arnim Pause
-
Patent number: 7338759Abstract: HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.Type: GrantFiled: May 23, 2001Date of Patent: March 4, 2008Assignee: Washington UniversityInventors: Charles M. Rice, Keril J. Blight
-
Publication number: 20080044884Abstract: Provided is a method and device for separating a cell from a sample. The method comprises contacting a nonplanar solid substrate with a cell-containing sample in a liquid medium having a pH of 3.0 to 6.0.Type: ApplicationFiled: August 20, 2007Publication date: February 21, 2008Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kyu-youn Hwang, Sung-young Jeong, Joon-ho Kim, Hun-joo Lee, Jung-im Han
-
Publication number: 20080044885Abstract: Provided is a method of separating microorganisms from a sample including contacting the sample containing microorganisms with an inorganic ion exchange material such that the sample reacts with the inorganic ion exchange material, and contacting the reacted sample with a means for capturing microorganisms.Type: ApplicationFiled: August 20, 2007Publication date: February 21, 2008Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kyu-youn HWANG, Sung-young JEONG, Joon-ho KIM
-
Patent number: 7332176Abstract: Unique Solenopsis invicta viruses (SINV) have been identified and their genome sequenced. Oligonucleotide primers have been developed using the isolated nucleic acid sequences of the SINV. The viruses are used as a biocontrol agent for control of fire ants.Type: GrantFiled: September 29, 2005Date of Patent: February 19, 2008Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Steven M. Valles, Roberto M. Pereira, Wayne B. Hunter, David H. Oi, Charles A. Strong, Phat M. Dang, David F. Williams
-
Patent number: 7326555Abstract: A process for purifying virus particles, especially recombinant adenovirus vector particles, is presented. The process relies on various combinations of cell lysis, detergent-based precipitation of host cell contaminants away from the virus, depth filtration or centrifugation, ultrafiltration, nuclease digestion and chromatography to robustly and economically produce highly purified product. This process results in contaminating DNA levels which are consistently below detectable levels.Type: GrantFiled: May 13, 2003Date of Patent: February 5, 2008Assignee: Merck & Co., Inc.Inventors: John O. Konz, Jr., Ann L. Lee, Chi Shung Brian To, Aaron R Goerke
-
Publication number: 20080014625Abstract: A disposable, virus-trapping membrane, and a corresponding method to remove viruses from solution are described. The membrane includes a disposable, micro-porous filter membrane and a ligand immobilized on the membrane. The ligand irreversibly and selectively binds viruses. The ligand also has a pKa sufficiently high to repel antibodies via electrostatic charge repulsion.Type: ApplicationFiled: July 12, 2007Publication date: January 17, 2008Inventor: Mark R. Etzel
-
Patent number: 7319002Abstract: A method for isolating, from a mixture, a virus having a surface protein with a binding site for sialic acid is provided. The method involves contacting the mixture with mucin which has been linked to a solid support and washing the solid support to remove material from the mixture is non-specifically bound to the mucin-linked support. Thereafter, the specifically bound virus (e.g., AAV4 or AAV5) may be removed in a further washing step utilizing a concentrated slat or solution with low pH. Also described are pharmaceutical kits containing solid supports linked to mucin for use in isolating virus having a surface protein with a binding site for sialic acid, or detecting the presence of the virus in a biological sample.Type: GrantFiled: August 6, 2002Date of Patent: January 15, 2008Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Alberto Auricchio, Markus Hildinger
-
Patent number: 7314746Abstract: Apparatus and methods are described for pharmaceutical grade manufacture extrachromosomal nucleic acids from cell lysates using flotation to separate and eliminate undesired insoluble cellular debris including chromosomal DNA from the lysates. A gas is introduced to controllably generate bubbles that reduce the density of the cell debris and create a buoyant flocculent phase that can be readily separated from, and thus provide, a substantially clarified fluid lysate phase that is enriched in extrachromosomal DNA but substantially depleted of cellular proteins and chromosomal DNA.Type: GrantFiled: September 12, 2003Date of Patent: January 1, 2008Assignee: Valentis, Inc.Inventors: Kwok-Leung (Jacky) Au-Yeung, Lee B. Bussey
-
Patent number: 7312064Abstract: The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus.Type: GrantFiled: March 29, 2005Date of Patent: December 25, 2007Assignee: St. Jude Children's Research HosptalInventor: Erich Hoffmann
-
Patent number: 7300785Abstract: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure the production of endogenous interferons by said cell line.Type: GrantFiled: January 31, 2006Date of Patent: November 27, 2007Assignee: Universiteit GhentInventors: Peter Meerts, Hans Nauwynck
-
Patent number: 7294500Abstract: The invention relates to Infectious Bursal Disease Virus (“IBDV”) and vaccines therefor. Provided are infectious recombinant Infectious Bursal Disease Virus (“rIBDV”) essentially incapable of growing in a cell that is not derived from a bursa cell, or an infectious rIBDV having retained at least part of the very virulent characteristics of a very virulent Infectious Bursal Disease Virus (“vvIBDV”).Type: GrantFiled: January 14, 2002Date of Patent: November 13, 2007Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Hendrik Johannis Boot, Anna Agnes H. M. ter Huurne, Bernardus Petrus H. Peeters
-
Patent number: 7291498Abstract: A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the 5? inverted terminal repeat, the left terminus spans the E4 region and the 3? inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.Type: GrantFiled: June 20, 2003Date of Patent: November 6, 2007Assignee: The Trustees of the University of PennsylvaniaInventors: Soumitra Roy, James M. Wilson
-
Patent number: 7291342Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.Type: GrantFiled: May 17, 2004Date of Patent: November 6, 2007Assignee: Intervet International B.V.Inventors: Lillian Melson, Faris Jirjis
-
Publication number: 20070254352Abstract: The present invention provides methods of purifying encapsidated virus, e.g., viral particles comprising viral nucleic acid, from compositions comprising encapsidated viral nucleic acid and viral particles that lack viral nucleic acid; methods for reducing the particle:genome ratio in a preparation of encapsidated viral nucleic acid; and methods for selectively inactivating viral particles that lack viral nucleic acid in a liquid composition comprising encapsidated viral nucleic acid and the viral particles that lack viral nucleic acid. The methods generally involve subjecting the composition to hydrostatic pressure such that the viral particles lacking viral nucleic acid are selectively inactivated.Type: ApplicationFiled: April 24, 2007Publication date: November 1, 2007Inventors: David V. Schaffer, Joshua N. Leonard
-
Patent number: 7285424Abstract: A membrane-based assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes a self-calibrated magnetic binding assay format (e.g., sandwich, competitive, etc.) that includes detection probes capable of generating a detection signal (e.g., fluorescent non-magnetic particles) and calibration probes capable of generating a calibration signal (e.g., fluorescent magnetic particles). The amount of the analyte within the test sample is proportional (e.g., directly or inversely) to the intensity of the detection signal calibrated by the intensity of the calibration signal. It has been discovered that the fluidics-based device of the present invention provides an accurate, inexpensive, and readily controllable method of determining the presence of an analyte in a test sample.Type: GrantFiled: August 27, 2002Date of Patent: October 23, 2007Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Xuedong Song, Rosann Kaylor
-
Patent number: 7270990Abstract: An improved process for recovery of virus from allantoic fluid of virus-infected chick embryos. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing viral yield. Dissociation can be achieved by subjecting the virus-debris complex to conditions of increased salt concentrations, e.g., 0.5 M or greater.Type: GrantFiled: June 18, 2004Date of Patent: September 18, 2007Assignee: Microbix Biosystems, Inc.Inventors: Gregory V. Williams, Kenneth Hughes
-
Patent number: 7264923Abstract: A norovirus-permissive cell culture infected with a norovirus, and methods of culturing a norovirus, are disclosed. Norovirus-permissive cells include dendritic cell-lineage cells, and macrophage-lineage cells, such as dendritic cells, and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway. Also disclosed are methods of screening anti-viral compounds against norovirus-permissive cells infected with norovirus, and norovirus adapted to grow in fibroblasts as well as macrophages that are not deficient in a cellular anti-viral pathway. Methods of making a norovirus vaccine are also disclosed.Type: GrantFiled: May 5, 2004Date of Patent: September 4, 2007Assignee: Washington UniversityInventors: Herbert W. Virgin, Christiane Wobus, Stephanie Karst
-
Patent number: 7264958Abstract: The invention concerns a method for purifying a crude viral preparation containing viral, in particular adenoviral, particles of interest. The invention is characterised in that it comprises a step of adsorption on a fluidised bed. The invention also concerns a protocol for producing viral particles for use in gene therapy comprising such a purifying process.Type: GrantFiled: February 21, 2000Date of Patent: September 4, 2007Assignee: Transgene, S.A.Inventors: Michel Koehl, David Gaillac
-
Patent number: 7252984Abstract: The present invention relates to new attenuated mutant New Castle's disease La SotaNewcastle disease virus strains suitable for in ovo vaccination of avian species comprising a mutation in the gene sequences encoding the HN and/or F glycoproteins of said virus. Furthermore, the invention relates to a vaccine composition comprising said attenuated mutant Newcastle's disease La Sota virus strain, and to the use thereof for the preparation of a vaccine for in ovo vaccination of avian species against Newcastle's disease.Type: GrantFiled: October 2, 2002Date of Patent: August 7, 2007Assignee: Centrum Voor Onderzoek in Diergeneeskunde en AgrochemieInventors: Jan Mast, Guy Meulemans
-
Patent number: 7244558Abstract: The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an operable promoter. Within the scope of the invention are vaccines comprising the attenuated, infectious NDV. Also disclosed are methods of making the vaccines and methods of using the vaccines to prevent or treat Newcastle disease in an avian host. The present invention also concerns the nucleotide sequences of the entire genome of NDV, the leading region, the trailing region, and the NP region, as well as proteins encoded by these nucleotide sequences.Type: GrantFiled: May 5, 2000Date of Patent: July 17, 2007Assignees: University of Maryland, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Siba K. Samal, Peter L. Collins
-
Patent number: 7235394Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.Type: GrantFiled: November 6, 2003Date of Patent: June 26, 2007Assignee: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Patent number: 7235235Abstract: The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.Type: GrantFiled: March 13, 2003Date of Patent: June 26, 2007Assignee: University of North Carolina at Chapel HillInventors: Robert E. Johnston, Nancy L. Davis, Jonathan F. Smith, Peter Pushko, Michael Parker, George Ludwig
-
Patent number: 7235391Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60–100% of the starting infectivity.Type: GrantFiled: August 28, 2001Date of Patent: June 26, 2007Assignee: Introgen Therapeutics, Inc.Inventors: Zheng Wu, Shuyuan Zhang
-
Patent number: 7235393Abstract: A method for isolating AAV viruses from cellular DNA of non-human primate (NHP) tissues by transfecting the DNA of NHP into 293 cells, rescuing the virus and amplifying it through serial passages in the presence of adenovirus helper functions is provided. Also provided are kits useful for performing this method.Type: GrantFiled: April 22, 2003Date of Patent: June 26, 2007Assignee: The Trustees of the University of PennsylvaniaInventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
-
Patent number: 7232680Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.Type: GrantFiled: April 22, 2002Date of Patent: June 19, 2007Assignee: Pfizer Inc.Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
-
Patent number: 7226775Abstract: A method of removing bacterial endotoxin from a pharmaceutical process solution is disclosed. In one embodiment, the method comprises treating the solution with a surfactant effective to dissociate the endotoxin from a pharmaceutical drug or vaccine substance in the solution, and then filtering the solution through a molecular cut-off filter having a pore size effective to retain the pharmaceutical drug or vaccine substance but allow the dissociated bacterial endotoxin to pass therethrough.Type: GrantFiled: March 12, 2001Date of Patent: June 5, 2007Assignee: Medeva Europe LimitedInventors: Bridget Kathleen Mapleson, Philip Sizer
-
Patent number: 7223584Abstract: Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of anti-rabies immunity in a subject.Type: GrantFiled: October 10, 2002Date of Patent: May 29, 2007Assignee: Thomas Jefferson UniversityInventors: Bernhard Dietzschold, D. Craig Hooper, Matthias J. Schnell
-
Patent number: 7223585Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.Type: GrantFiled: April 29, 2003Date of Patent: May 29, 2007Assignee: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Patent number: 7223595Abstract: The present invention provides methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE protease mixture in a single affinity chromatography step and uses of the purified SGT.Type: GrantFiled: September 17, 2004Date of Patent: May 29, 2007Assignee: Baxter Healthcare S.A.Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
-
Patent number: 7205013Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: GrantFiled: October 25, 2004Date of Patent: April 17, 2007Assignee: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Patent number: 7195905Abstract: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.Type: GrantFiled: December 10, 2001Date of Patent: March 27, 2007Assignee: Baxter Healthcare S.A.Inventors: Otfried Kistner, Manfred Reiter, Axel Bruehmann, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
-
Patent number: 7186504Abstract: The invention provides cell lines which are useful for the rapid detection of enteroviruses. In particular, the invention provides transgenic African green monkey kidney cell lines and buffalo green monkey kidney cell lines. The invention provides cell lines which have increased sensitivity to infection by enteroviruses in single-cell type and mixed-cell type cultures compared to other cell types which are currently used for enterovirus detection. The cells of the invention also are permissive to infection by a larger number of enteroviruses as compared to the cell type from which they were derived.Type: GrantFiled: June 3, 2004Date of Patent: March 6, 2007Assignee: University Hospitals of ClevelandInventor: Yung T. Huang
-
Patent number: 7172893Abstract: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.Type: GrantFiled: July 26, 2002Date of Patent: February 6, 2007Assignee: University of North Carolina at Chapel HillInventors: Joseph E. Rabinowitz, Richard Jude Samulski, Weidong Xiao
-
Patent number: 7160549Abstract: The present invention provides methods for making compositions including siderophore receptor polypeptides and porins from gram negative microbes. The methods include providing a gram negative microbe, disrupting the microbe, solubilizing the disrupted microbe, and isolating the polypeptides.Type: GrantFiled: April 22, 2004Date of Patent: January 9, 2007Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Patent number: 7153510Abstract: The invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers, and have use as vaccines. The recombinant vesiculoviruses can also be inactivated for use as killed vaccines.Type: GrantFiled: May 4, 1995Date of Patent: December 26, 2006Assignee: Yale UniversityInventor: John K. Rose
-
Patent number: 7147848Abstract: The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3?NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain.Type: GrantFiled: June 19, 2002Date of Patent: December 12, 2006Assignee: The Research Foundation of State University of New YorkInventors: Matthias Gromeier, Eckard Wimmer
-
Patent number: 7141406Abstract: A method of enriching a solution for an adenovirus comprising contacting a solution containing an adenovirus with an anion exchange chromatography resin comprising an acrylate or sulphonamide linker such that the adenovirus binds to the chromatography resin and eluting the adenovirus from the resin with an eluant to obtain an enriched solution of adenovirus.Type: GrantFiled: May 5, 2003Date of Patent: November 28, 2006Assignee: GenVec, Inc.Inventors: Miguel E Carrion, Marilyn Menger, Imre Kovesdi
-
Patent number: 7132271Abstract: Methods for enhancing the production of viral vaccines in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain interferon induced antiviral activities, in particular, cellular levels of double-stranded RNA (dsRNA) dependent kinase (PKR) and 2?-5? oligoadenylate synthetase (2-5A synthetase). In cell cultures deficient for PKR or 2-5A synthetase, viral yield is enhanced by several orders of magnitude over cell cultures with normal levels of these proteins making these cell cultures useful for the production of viral vaccines.Type: GrantFiled: November 24, 2003Date of Patent: November 7, 2006Assignee: The Regents of the University of CaliforniaInventor: Allan S. Lau
-
Patent number: 7129342Abstract: The present invention relates to nucleic acid sequence which comprises the genome of an infectious GB virus B clone. The invention also relates to the use of the nucleic acid sequence of the infectious GB virus B clone to indirectly study the molecular properties of HCV, and in the production of HCV/GBV-B chimeras. The invention further relates to the use of the infectious nucleic acid sequence of GB virus B clone and the HCV/GBV-B chimeras in the development of vaccines and therapeutics for HCV.Type: GrantFiled: June 2, 2000Date of Patent: October 31, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jens Bukh, Masayuki Yanagi, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 7125706Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: GrantFiled: June 12, 2001Date of Patent: October 24, 2006Assignee: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Shawn Gallagher
-
Patent number: 7118740Abstract: A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 1012 pfus and is delivered by direct injection into a group of cancer cells or via intravenous injection.Type: GrantFiled: September 22, 2000Date of Patent: October 10, 2006Assignee: Mayo Foundation for Medical Education and ResearchInventors: Stephen James Russell, Adele Fielding, Kah-Whye Peng, Deanna Grote